



Appendix B: Antibiotic Treatment Recommendations for Acute Exacerbations of COPD (AECOPD)

CATEGORY	RECOMMENDED EMPIRIC THERAPY (ALPHABETICAL ORDER)	NOTES
<p>< 4 exacerbations/year and at least 2 of the following:</p> <ul style="list-style-type: none"> • increased sputum purulence • increased sputum volume • increased dyspnea 	<p>First line agents:</p> <p style="text-align: center;">amoxicillin 1 g PO TID or doxycycline 200 mg PO once, then 100 mg PO BID or sulfamethoxazole-trimethoprim 1 DS (800-160 mg) tablet PO BID</p> <p>Failure of first line agents: see below</p>	<p>Treat for 5 to 7 days. Evidence indicates that 5 days of treatment may be as effective as 7 to 10 days.</p>
<p>≥ 4 exacerbations/year and at least 2 of the following:</p> <ul style="list-style-type: none"> • increased sputum purulence • increased sputum volume • increased dyspnea <p>or</p> <p>Failure of first line agents above¹</p> <p>or</p> <p>Antibiotics in the past 3 months²</p>	<p>First line agents:</p> <p style="text-align: center;">amoxicillin-clavulanate 875-125 mg PO BID for 5 to 10 days or cefuroxime axetil 500 to 1000 mg PO BID for 5 to 10 days or levofloxacin3 750 mg PO once daily for 5 days</p> <p>Alternatives:</p> <p style="text-align: center;">azithromycin4 500 mg PO BID for 3 days or clarithromycin4 500 mg PO BID or 1000 mg extended-release (XL) PO once daily for 5 to 10 days</p>	<ol style="list-style-type: none"> 1. Failure of first line agents: no improvement in symptoms following completion of antibiotic therapy OR clinical deterioration after 72 hours of antibiotic therapy. 2. Use a different antibiotic class than was used previously. 3. Due to the broad spectrum of levofloxacin, potential for increasing resistance and risk of <i>C. difficile</i> infection, reserve this medication for beta-lactam allergies or failure to first line antibiotic therapy. 4. Macrolides have poor <i>Haemophilus</i> coverage and significant <i>S. pneumoniae</i> resistance. The benefit of macrolides may be due more to anti-inflammatory properties than to antibacterial activity.

References

- Blondel-Hill E, Fryters S. Bugs & Drugs 2012. 2012 edition. Edmonton, AB: Alberta Health Services; 2012.
Canadian Pharmacists Association. Chronic Obstructive Pulmonary Disease. Revised: July 2015.